Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2008

View Archived Issues

Mutations behind Duane's retraction syndrome identified

Background data on CR-845 presented during recent World Congress on Pain

Preliminary phase II results show pain relief with XEN-2127 in oncology patients

Terlipressin benefits patients awaiting liver transplant with renal failure, hyponatremia

ALK-Abello reports positive results from phase II/III of allergy vaccine against dust mites

Rosetta enters collaboration with NIH to identify microRNAs involved in HIV viral replication

Pipex acquires AT-001 for rheumatoid arthritis

DelSite files IND with the FDA for phase I safety and immunogenicity study of GelVac

New therapeutic agents for obesity described in recent patents

Recent patent literature discloses new anticancer agents

New treatment options for osteoporosis disclosed in recent Novartis patent

V-2006 development for Parkinson's disease advances

Biovex receives regulatory clearance to begin studies with ImmunoVEX-HSV2

PolyMedix commences dosing in phase I novel systemic antibiotic trial

Repros reports no tumors in completed Proellex animal carcinogenicity study

Vidaza receives expanded FDA approval in high-risk MDS patients

Metvix prevents precancerous lesions in transplant patients

Ardea Biosciences commences phase I trials for gout candidate RDEA-594

Cymbalta approved in Europe for the treatment of generalized anxiety disorder

FDA fast tracks ferumoxytol for vascular-enhanced magnetic resonance imaging

Phase III trial commences for Nexavar as adjuvant therapy in liver cancer

Auris Medical reports results of phase I/II AM-101 trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...